Skip to main
BDTX
BDTX logo

BDTX Stock Forecast & Price Target

BDTX Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Black Diamond Therapeutics Inc is poised for significant growth as it approaches several catalysts that may drive its stock value upward by over 100%, particularly through improvements in treatment efficacy and response durability in upcoming clinical trials. With forecasted sales of approximately $500-750 million anticipated from positive overall response rates (ORR) expected in the second half of 2025, the company stands to benefit from strong market positioning as it targets actionable oncogenic mutations. The potential for high M&A valuations, with estimates suggesting a 3-6 times upside based on comparable oncology acquisitions, further supports a robust outlook for the company’s financial health and stock performance.

Bears say

Black Diamond Therapeutics Inc. is facing significant skepticism about its pipeline, particularly regarding its drug silevertinib, which has resulted in a market capitalization of approximately $230 million reflecting low investor confidence. Concerns have been raised regarding its dosing and competitive positioning within the first-line EGFR-NCM patient population, with fears that upcoming clinical trials may reveal diminished efficacy when a broader representation of patient mutations is considered. Additionally, the mixed results of recent clinical updates have led to investor disappointment and may overshadow potential opportunities in other therapeutic areas, contributing to an overall negative outlook for the company’s stock performance.

BDTX has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Black Diamond Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Black Diamond Therapeutics (BDTX) Forecast

Analysts have given BDTX a Strong Buy based on their latest research and market trends.

According to 5 analysts, BDTX has a Strong Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Black Diamond Therapeutics (BDTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.